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Endoscopic Evaluation of Gastro-Esophageal
Reflux Disease
David Armstronga
Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario,
Canada
Endoscopy is, currently, the initial investigation ofchoicefor the investigation ofgastroesophageal
reflux disease (GERD) in clinicalpractice and clinical research. Erosion severity ispredictive ofa
patient's response to therapy and ofthe likelihood ofrelapse after therapy. It is, therefore, impor-
tant to grade the severity oferosive reflux esophagitis, particularly in the context ofclinical trials.
The Savary-Miller endoscopic classification system is used widely but usage and interpretation are
very variable. The "MUSE" (metaplasia [M1, ulceration [U], stricturing [S]anderosions[EJ) clas-
sification provides clear definitions ofthe relevant endoscopicfeatures, and it is based on a stan-
dardized reportform, which allows the endoscopist to make a clear record ofesophagitis severity.
Recent studies confirm thatendoscopists can identify erosions ormucosal breaks, ulcers, strictures,
and metaplasia reproducibly. The "L.A." (Los Angeles) classification describes four grades of
esophagitis severity (A toD), basedon the extentofesophageallesions known as "mucosalbreaks,"
but itdoes not record thepresence orseverity ofother GERD lesions. Thus,forpatients with "com-
plicated" reflux disease, the "MUSE" classification offers a more comprehensive description of
esophagitis severity.
Endoscopy is not universally applicable: 40 to 60percent ofpatients with typical reflux symptoms
do not have esophageal erosions and are now considered to have "endoscopy negative reflux dis-
ease" (ENRD). Thus, endoscopy is not thefinal arbiteras to a diagnosis ofreflux disease, and it is
not, therefore, a necessary prerequisite to therapy. Endoscopy is indicated atfirstpresentationfor
patients with alarm symptoms referable to the uppergastrointestinal tract. Ithasalso beenproposed
that allpatients with chronic GERD should have a "once-in-a-lifetime" endoscopy; in the absence
ofBarrett's esophagus or other complications, nofollow-up is required unless thepatient's symp-
toms change significantly. A surveillanceprogram withmultiplebiopsiesshouldbe institutedifthere
is evidence ofBarrett's esophagus. Endoscopic evaluation shoulddocument thepresence andextent
ofesophageal erosions using the L.A. or MUSE classification systems; complications should also
be documented and may be recorded using the MUSE classification. Non-erosive changes such as
erythema may be ignored on the basis ofpresent evidence, and there are no clear data to support
the use ofendoscopic biopsiesfor the diagnosis ofGERD.
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INTRODUCTION
For many years, esophageal erosions
have been considered the sine qua non of
reflux esophagitis and, hence, of gastro-
esophageal reflux disease (GERD)b. At
one end of the spectrum, lesions such as
ulceration, stricture formation, and
Barrett's esophagus are recognized to be
more severe manifestations or complica-
tions of GERD, whereas "minor" changes
such as erythema, edema, and friability
are considered to be markers of minor
esophageal damage.
However, since the introduction of
histamine H2-receptor antagonists, the
resolution of erosive esophagitis has been
the most common primary outcome mea-
sure used for therapeutic trials in GERD.
Patients with more severe lesions, or com-
plications ofGERD, are rarely enrolled in
therapeutic trials, while patients with
minor endoscopic changes may be
enrolled, but theirresults are often exclud-
ed from the final analysis.
DIAGNOSIS OF EROSIVE REFLUX
ESOPHAGITIS
Erosive esophagitis is now consid-
ered, by many, to be synonymous with
GERD, and the diagnosis of GERD is
often, therefore, predicated on the obser-
vation of esophageal erosions. Of the
diagnostic techniques available for inves-
tigating GERD, upper gastrointestinal
radiology has low sensitivity and speci-
ficity for the detection of erosions and
Barrett's esophagus, although it is some-
what better for the diagnosis of ulceration
or stricturing. Esophageal acid exposure,
quantified by ambulatory pH monitoring,
correlates well with the degree of
esophageal damage, but this technique
cannot be used to diagnose erosive
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Figure 1. Recurrence of erosive esophagitis is rare in the absence of recurrent reflux
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Figure 2. A pictorial representation of the "MUSE" classification system, which can
be used as the basis for an endoscopic report form. Metaplasia, Ulceration, Stricture
formation and Erosions (M.U.S.E.) are assessed and graded independently according to
their degree of severity (0: absent, 1: mild, 2: severe). For each lesion type, the appropriate
box is ticked and, if relevant, the extent of a lesion such as columnar metaplasia may be
marked with reference to the diaphragmatic hiatus. Examples of some MUSE classifica-
tions and the corresponding endoscopic appearances are: M2UoS1E,: active (with ero-
sions) peptic stricture with a diameter greater than 9 mm, situated at e upper pole of a
circumferential area of columnar metaplasia; M2U2S E large, confluent ulcers associated
with a circumferential area of columnar metaplasia; 1AJOSOES : erosions affecting only one
fold. (Courtesy of Ref. [12]). 0a0i 0 V
esophagitis per se, and it certainly cannot
be used to document resolution of erosive
esophagitis. Upper gastrointestinal
endoscopy has, therefore, become the pre-
dominant diagnostic modality for GERD
in clinical and research practice.
In the context of managing erosive
esophagitis, endoscopy has significant
advantages: it can be used to document the
presence and extent of esophageal ero-
sions as well the presence of ulceration,
stricturing, and Barrett's esophagus or
columnar metaplasia. It must be supple-
mented by biopsy for the diagnosis of
metaplasia and the potential sequelae of
dysplasia and neoplasia; endoscopic biop-
sy, with or without brushings, also facili-
tates the diagnosis of other infective
esophagitides and malignancies. However,
although changes such as elongation ofthe
stromal papillae [1], aneutrophil infiltrate,
an eosinophil infiltrate [2, 3] and "bal-
loon" cells [4] have all been described in
association with gastroesophageal reflux
disease, the sensitivity, and specificity of
these findings for the diagnosis of GERD
have not been defined, and the role ofhis-
tology, therefore, remains undefined.96 Armstrong: Endoscopic evaluation ofGERD
In general, thecomplications ofGERD
are relatively infrequent, and the most fre-
quent identifiable lesion remains the
esophageal erosion or "touche peptique"
described by Savary [5]. For patients with
erosive esophagitis, the recurrence of
symptoms aftertherapy correlates well with
the recurrence of esophageal erosions
(Figure 1) [6]. Neither the extent nor the
severity oferosions correlates directly with
symptom severity in an individual patient;
however, erosion severity is predictive of a
patient's probable response to therapy and
also ofthe likelihood ofrelapse after cessa-
tion of therapy, unlike the presence of
minor, non-erosive changes [7, 8]. It is,
therefore, important to grade the severity of
erosive reflux esophagitis, particularly in
the context ofclinical trials.
ENDOSCOPIC GRADING OF
ESOPHAGITIS SEVERITY
The most widely used classification
system is that described first by Savary &
Miller, in which disease severity is graded
according to the extent ofesophageal ero-
sions [9]. The Savary-Miller classification
recognizes also that complications of
GERD are important but, in both versions
described by the authors [9, 10], they are
grouped together as high-grade esophagi-
tis (Grade 4 or Grade 5), regardless of
whether or not there are concomitant ero-
sions. In consequence, it is very difficult to
use the Savary-Miller classification to doc-
ument the healing oferosive esophagitis in
patients with complicated disease. The
recognition that metaplasia (M), ulceration
(U), stricturing (S) and erosions (E) can
occur independently of each other led to
the formulation ofthe "MUSE" classifica-
tion; in this case, the classification of ero-
sion severity (Eo to E2) is based on the
Savary-Miller classification, but it is sup-
plemehted by independent gradings of
severity forulcers(UO toU2), strictures (SO
to S2) and metaplasia (Mo to M2) (Figure
2). This classification provides cleardefin-
itions of the different endoscopic features
ofGERD and is based on apictorial report
form, which allows the endoscopist to
make a clear record ofesophagitis severity
[11, 12].
In recent years, it has become clear
that the profusion ofclassification systems
has made it increasingly difficult to com-
pare the results ofdifferent therapeutic tri-
als in GERD. This prompted the formation
of an International Working Group
charged with developing a standardized
endoscopic esophagitis classification sys-
tem, which would be generally acceptable
in clinical or research practice. In an ini-
tial step, the group identified endoscopic
Table 1. Diagnostic agreement between expert endoscopists (kappa values) for the
identification of "mucosal" breaks [13].
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Figure 3. Kappa scores for evaluation of endoscopic features of complicated reflux
esophagitis by 29 experienced endoscopists {E) and 13 novices (N), based on
reporting of endoscopic video recordings and slide material. A kappa score > 0.70
(dashed, horizontal line). is considered to indicate god agreement between observers. With
permission from Ref. [13].
features, associated with GERD, which
could be recognized reproducibly by
endoscopists. These studies, based on
high-quality 35 mm slides and video
recordings of esophageal endoscopies,
indicate that endoscopists can identify
reliably, erosions or mucosal breaks, par-
ticularly ifthey have an overlying exudate
(Table 1) as well as ulcers, strictures and
metaplasia (Figure 3). This study suggest-
ed also that experienced endoscopists
could identify reliably, some of the minor
changes (erythema, edema, friability)
attributable to reflux [13]. In conjunction
with this, the group formulated anew clas-
sification system - the "L.A." classifica-
tion (first presented at the 1992 World
Congress of Gastroenterology in Los
Angeles) - which described four grades
of esophagitis severity (Grade A to Grade
D) based on the extent ofmucosal breaks.
The term "mucosal break" was coined to
encompass erosions as well circumscribed
areas of erythema since it was felt there
were no clear criteria for distinguishing
between a "denuded" erosion and an ero-
sion covered by "slough" or an "exudate."
The term "mucosal break" is also intended
to include ulcers since there are no defined
criteria for determining when an erosion
deepens sufficiently to become an ulcer.
Validation studies with the current version
of the L.A. classification system indicate
that the higher grades of esophagitis are
associated with lower healing rates and
higher relapse rates. Since it is based on
endoscopic features, which can be identi-
fied reproducibly by endoscopists, the
L.A. classification has the potential to be a
generally-accepted, standardized classifi-
cation system for erosive esophagitis.
However, the L.A. classification does not
record the presence or severity of other
GERD lesions, which are, themselves,98 Armstrong: Endoscopic evaluation of GERD
identified reliably by endoscopists; thus in
clinical practice and in therapeutic trials
that include patients with "complicated"
reflux disease, the MUSE classification
offers a more comprehensive description
of esophagitis severity.
LIMITATIONS OF ENDOSCOPY
Despite its importance in clinical and
research practice, endoscopy is not, how-
ever, universally applicable. It is inappro-
priate for the diagnosis ofhiatal herniation
or esophageal dysmotility. More impor-
tantly, there is an increasing recognition of
"endoscopy negative reflux disease"
(ENRD): recent studies suggest that 40 to
60 percent of patients with typical reflux
symptoms do not, in fact, have esophageal
erosions [14, 15]. For some physicians,
this represents proof final that these
patients do not have GERD and, in some
jurisdictions, that these patients do not
merit therapy with proton pump inhibitors.
Despite this, many such patients will have
evidence of a temporal correlation
between reflux episodes and symptoms
during esophageal pH monitoring studies,
and their symptoms will often be relieved
by medical anti-reflux therapy [14, 15].
Thus, it is becoming clear that the clinical
spectrum of GERD does include ENRD
and that endoscopy is not, therefore, the
final arbiter as to a diagnosis ofreflux dis-
ease.
ROLE OF ENDOSCOPY FOR
EVALUATION OF GERD
What then is the place of endoscopy
in clinical practice? Endoscopic confirma-
tion of esophageal erosions is highly spe-
cific for a diagnosis of GERD, but it has
low sensitivity, and there is, therefore, the
danger that endoscopy alone will underes-
timate greatly the prevalence of GERD.
An outcomes study has shown [16] that
endoscopy leads to a significant change in
therapy for patients with reflux symptoms,
but the change was most marked in
patients who had erosive esophagitis; it is
not clear that the failure to alter therapy in
patients with ENRD was appropriate. It
has been argued that endoscopy is not nec-
essary to make a diagnosis of GERD in a
patient with typical symptoms unless there
is a suspicion of serious underlying dis-
ease based on the patient's age or alarm
symptoms such as weight loss, dysphagia,
anemia or gastrointestinal blood loss. If
reimbursement policies mandate a con-
firmed diagnosis of erosive esophagitis
before effective antisecretory therapy can
be started, endoscopy shouldbe performed
early, and, if possible, the patient should
stop acid antisecretory or prokinetic thera-
py at least one to two weeks prior to
endoscopy. If erosive esophagitis is con-
firmed, there seems to be no reason to
repeat endoscopy simply to confirm heal-
ing since there is a good correlation
between symptoms and the recurrence of
erosions [6]. In the majority of patients,
GERD is a chronic, relapsing condition,
and the only indication for repeat
endoscopy would be a significant change
or worsening ofthe patient's symptoms.
For the present, the other major indi-
cation for endoscopy is the exclusion of
Barrett's esophagus. There is continuing
controversy over the advisability of sur-
veillance follow-up for patients with
Barrett's esophagus, but a cost-modeling
study suggests that it is cost-effective, if
the incidence of carcinoma in Barrett's
exceeds 1 percent [17]; this provides sup-
port for current recommendations that
endoscopic surveillance be conducted
every two years in patients with confirmed
Barrett's esophagus. The natural history of
Barrett's esophagus is still unclear but data
from Olmsted County [18] suggest that the
area ofinvolved mucosa does not progress
significantly with time over follow-upArmstrong: Endoscopic evaluation ofGERD 99
periods of three to eight years. Thus, on
present evidence, it would seem reason-
able to suppose that apatient who does not
have Barrett's esophagus at the time of
diagnosis is unlikely to develop metaplasia
subsequently. This has led to the concept
of a "once-in-a-lifetime" endoscopy for
patients with GERD. Under this model,
there would be no need to perform an
endoscopy before embarking on therapy
but one examination should be performed
- during ongoing therapy - to exclude
Barrett's and to minimize the likelihood of
confusion between the histological
changes of acute inflammation and those
ofmetaplasia or dysplasia.
CONCLUSION
In the long run, the role ofendoscopy
will change as more is learned about the
natural history ofsymptomatic GERD and
its relationship to erosive esophagitis,
about the natural history of Barrett's
esophagus and its progression to
esophageal adenocarcinoma and about the
importance of carditis and its relationship
to the increasing incidence of adenocarci-
noma ofthe cardia.
Endoscopic evaluation of a patient
with reflux symptoms reassures thepatient
and the physician that no complications of
GERD or other potentially serious condi-
tion has been overlooked. It also provides
some indication as to the most appropriate
therapy, the likelihood ofresponse to ther-
apy, and the likelihood of subsequent
relapse. Against these advantages must be
weighed the potential financial cost of the
procedure to the patient and the health care
system. Endoscopy is relatively costly, but
the absolute cost varies considerably;
complications from upper gastrointestinal
endoscopy are very infrequent, but they
have been recorded. The major disadvan-
tage of endoscopy arises from the notion
that GERD is synonymous with erosive
esophagitis; this may lead to a failure to
diagnose GERD and, hence, to inappropri-
ate or inadequate therapy for ENRD.
For the present, endoscopy is not a
necessary prerequisite to therapy for typi-
cal reflux symptoms, but it is indicated at
first presentation for patients with alarm
symptoms referable to the upper gastroin-
testinal tract. Whenever it is performed,
endoscopic evaluation should document
the presence and extent ofesophageal ero-
sions using the L.A. or MUSE classifica-
tion systems; the presence and extent of
complications should also be documented
and may be recorded using the MUSE
classification. Non-erosive changes such
as erythema may be ignored on the basis
of present evidence and there are no clear
data to support the acquisition of endo-
scopic biopsies for the diagnosis of
GERD. However, a diagnosis of Barrett's
esophagus mustbe confirmedhistological-
ly and endoscopic biopsies are, therefore,
essential if the endoscopic appearances of
the distal esophagus suggest the develop-
ment of columnar metaplasia. An endo-
scopic surveillance program with multiple
biopsies should be instituted ifthere is his-
tological evidence of Barrett's esophagus,
provided that the patient would be willing
and able to undergo further therapy in the
event that dysplastic or neoplastic lesions
were identified. Endoscopic follow-up is
not required for uncomplicated erosive
reflux esophagitis or ENRD unless there
has been a significant change in the
patient's symptoms.
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